This site is intended for health professionals only
Saturday 21 April 2018
Share |

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Boehringer Ingelheim has announced that BI 695501, its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA). 







Ads by Google